58,392 Shares of Medtronic PLC $MDT Purchased by Sage Capital Advisors llc

Sage Capital Advisors llc bought a new position in Medtronic PLC (NYSE:MDT) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 58,392 shares of the medical technology company’s stock, valued at approximately $5,039,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of MDT. BlackRock Inc. raised its position in Medtronic by 0.7% during the second quarter. BlackRock Inc. now owns 114,020,787 shares of the medical technology company’s stock valued at $8,919,846,000 after acquiring an additional 838,220 shares in the last quarter. State Street Corp boosted its position in Medtronic by 2.7% in the 2nd quarter. State Street Corp now owns 63,399,315 shares of the medical technology company’s stock worth $5,005,320,000 after purchasing an additional 1,658,301 shares in the last quarter. Bank of America Corp DE boosted its position in Medtronic by 5.4% in the 1st quarter. Bank of America Corp DE now owns 26,015,003 shares of the medical technology company’s stock worth $2,254,200,000 after purchasing an additional 1,343,220 shares in the last quarter. First Eagle Investment Management LLC boosted its position in Medtronic by 37.2% in the 2nd quarter. First Eagle Investment Management LLC now owns 13,783,983 shares of the medical technology company’s stock worth $1,078,321,000 after purchasing an additional 3,739,288 shares in the last quarter. Finally, WCM Investment Management LLC acquired a new stake in shares of Medtronic during the 1st quarter worth approximately $965,922,000. 82.06% of the stock is owned by institutional investors and hedge funds.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: MiniMed exchange offer was oversubscribed: Medtronic announced it will exchange all of its remaining 252.8 million MiniMed Group (NASDAQ: MMED) shares. The transaction advances the separation of the diabetes-device business and could allow investors to value Medtronic’s continuing operations more directly. The reported 18.3% proration indicates demand exceeded the shares available in the offer. Medtronic Announces Preliminary Results of MiniMed Exchange Offer
• Positive Sentiment: Growth opportunities remain attractive: The global bioelectronic-medicine device market is projected to expand at approximately a 17% annual rate through 2030. Medtronic’s position in neuromodulation and closed-loop technologies could provide exposure to this expanding market. Global Bioelectronic Medicine Device Market 2026
• Neutral Sentiment: Valuation and outlook support the shares: Commentary highlights Medtronic’s modest valuation relative to the broader market and an improving growth outlook. Its latest reported quarter also exceeded earnings and revenue expectations, with revenue up 13.7% year over year. Medtronic’s Modest Valuation Meets an Improving Growth Outlook
• Negative Sentiment: Short interest increased significantly: A larger bearish position in MDT suggests some investors are positioning for weakness and may weigh on sentiment, despite the company’s fundamental catalysts. Medtronic Sees Significant Increase in Short Interest
• Negative Sentiment: BTIG lowered its price target: The firm reduced its target from $100 to $99, although it retained a “buy” rating. The cut signals somewhat less near-term upside and tempers the otherwise constructive analyst view. Medtronic Price Target Cut by BTIG Research

Insider Transactions at Medtronic

In related news, EVP Harry Kiil sold 1,483 shares of the business’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total value of $138,882.95. Following the completion of the sale, the executive vice president owned 42,186 shares of the company’s stock, valued at approximately $3,950,718.90. The trade was a 3.40% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.27% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on MDT shares. UBS Group lifted their target price on shares of Medtronic from $100.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, September 3rd. TD Cowen reiterated a “buy” rating and issued a $110.00 target price on shares of Medtronic in a research note on Wednesday, September 30th. Barclays raised shares of Medtronic to a “hold” rating in a report on Wednesday, October 7th. Mizuho set a $115.00 price target on shares of Medtronic in a research report on Wednesday, September 2nd. Finally, Stifel Nicolaus lifted their price objective on shares of Medtronic from $80.00 to $95.00 and gave the company a “hold” rating in a report on Wednesday, September 2nd. Eighteen investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $102.88.

Medtronic Price Performance

MDT stock traded up $0.45 during mid-day trading on Tuesday, reaching $92.38. 6,267,723 shares of the company’s stock were exchanged, compared to its average volume of 10,821,911. The company has a market cap of $118.16 billion, a price-to-earnings ratio of 22.73, a price-to-earnings-growth ratio of 2.02 and a beta of 0.55. The stock’s 50 day moving average is $90.38 and its 200 day moving average is $84.80. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.07 and a quick ratio of 1.54. Medtronic PLC has a 12-month low of $73.31 and a 12-month high of $106.33.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, beating the consensus estimate of $1.39 by $0.06. The company had revenue of $9.76 billion for the quarter, compared to analyst estimates of $9.55 billion. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. Medtronic’s quarterly revenue was up 13.7% compared to the same quarter last year. During the same period last year, the company earned $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, research analysts expect that Medtronic PLC will post 5.98 EPS for the current year.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Investors of record on Friday, September 25th will be paid a $0.72 dividend. The ex-dividend date of this dividend is Friday, September 25th. This represents a $2.88 dividend on an annualized basis and a yield of 3.1%. Medtronic’s dividend payout ratio (DPR) is currently 70.94%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.